Other Events ·
60 Degrees Pharmaceuticals, Inc. prepared a statistical analysis plan for an interim analysis of its tafenoquine trial…
SXTPW60 Degrees Pharmaceuticals, Inc.
60 Degrees Pharmaceuticals, Inc. prepared a statistical analysis plan for an interim analysis of its tafenoquine trial for severe babesiosis (NCT0627370). The interim analysis will occur on 10/30/26 or after 24 of 33 patients are randomized and followed for 50 days, with potential for early reporting if conditional power is at least 80%. The company intends to apply for a Commissioner's National Priority Review Voucher if trial results support a supplementary New Drug Application (sNDA) submission by Q1 2028. 60 Degrees Pharmaceuticals, Inc. is a pharmaceutical company developing drug candidates for infectious diseases.